Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 21, 2025
Subject: Announcement of an Extraordinary General Meeting (EGM) to elect new Board of Directors members following a governance dispute with the Novo Nordisk Foundation.
Financial Metrics
This filing is a corporate governance announcement and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Board Composition: A significant shift in the Board of Directors is anticipated. Chair Helge Lund, Vice Chair Henrik Poulsen, and independent members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay will not stand for re-election.
- Continuity: Non-independent member Kasim Kutay and employee-elected members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen, and Thomas Rantzau will remain on the Board.
- Foundation Dispute: The Board and the Novo Nordisk Foundation could not reach a common understanding regarding the future composition of the Board. The Board proposed selective renewal, while the Foundation sought extensive reconfiguration.
Outlook, Risks, and Management Commentary
Management Commentary: Chair Helge Lund stated that convening the EGM is in the best interest of the company and shareholders to provide clarity on future governance, acknowledging the Foundation's control of the majority of votes.
Upcoming Events:
- EGM Date: November 14, 2025.
- Investor Conference Call: October 21, 2025, at 15:00 CEST (9:00 am EDT).
Risks and Contingencies: The primary risk identified is the potential for significant governance restructuring driven by the Novo Nordisk Foundation, which holds majority voting power. The outcome of the EGM will determine the future strategic direction and oversight of the company.
Key Facts for Investor Verification
- Verify the specific slate of candidates proposed by the Novo Nordisk Foundation for the November 14, 2025, EGM.
- Review the separate press release from the Novo Nordisk Foundation referenced in this filing to understand their specific governance demands.
- Monitor the outcome of the EGM to assess potential changes in strategic leadership and board independence.
- Confirm the attendance and statements made during the October 21, 2025, investor conference call regarding the dispute.